| pubmed-article:8524649 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8524649 | lifeskim:mentions | umls-concept:C0039215 | lld:lifeskim |
| pubmed-article:8524649 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:8524649 | lifeskim:mentions | umls-concept:C0018517 | lld:lifeskim |
| pubmed-article:8524649 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:8524649 | pubmed:issue | 22 | lld:pubmed |
| pubmed-article:8524649 | pubmed:dateCreated | 1996-1-25 | lld:pubmed |
| pubmed-article:8524649 | pubmed:abstractText | An approach was sought to increase the half-life and target cell specificity of antisense oligodeoxynucleotides (oligos). A monoclonal antibody (MAb) was derived from mice immunised with an oligo complementary to a region (1-20) of the HIV genome. This MAb exerts a protective effect on the oligo from the degradation induced by plasma exonucleases in vitro and in vivo. Moreover the anti-oligo MAb dissociates from the oligo in the presence of its complementary sequence to allow hybridization of the two complementary strands. To direct the oligo to CD4+ cells the anti-oligo MAb was cross-linked to an anti-CD4 MAb. The heteroaggregate determines a 5-fold increase in the cellular membrane binding of the oligo to CD4+ lymphocytes. These findings suggest a new approach to enhancing the therapeutic action and the target specificity of antisense oligodeoxynucleotides useful for the selective inhibition of HIV replication in vivo. | lld:pubmed |
| pubmed-article:8524649 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8524649 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8524649 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8524649 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8524649 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8524649 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8524649 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8524649 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8524649 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8524649 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8524649 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8524649 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8524649 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8524649 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8524649 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8524649 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8524649 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8524649 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8524649 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8524649 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8524649 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8524649 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8524649 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8524649 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8524649 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:8524649 | pubmed:issn | 0305-1048 | lld:pubmed |
| pubmed-article:8524649 | pubmed:author | pubmed-author:MorelloJJ | lld:pubmed |
| pubmed-article:8524649 | pubmed:author | pubmed-author:ColnaghiM IMI | lld:pubmed |
| pubmed-article:8524649 | pubmed:author | pubmed-author:MénardSS | lld:pubmed |
| pubmed-article:8524649 | pubmed:author | pubmed-author:BalsariAA | lld:pubmed |
| pubmed-article:8524649 | pubmed:author | pubmed-author:PozziBB | lld:pubmed |
| pubmed-article:8524649 | pubmed:author | pubmed-author:MaierJ AJA | lld:pubmed |
| pubmed-article:8524649 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8524649 | pubmed:day | 25 | lld:pubmed |
| pubmed-article:8524649 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:8524649 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8524649 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8524649 | pubmed:pagination | 4603-7 | lld:pubmed |
| pubmed-article:8524649 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:8524649 | pubmed:meshHeading | pubmed-meshheading:8524649-... | lld:pubmed |
| pubmed-article:8524649 | pubmed:meshHeading | pubmed-meshheading:8524649-... | lld:pubmed |
| pubmed-article:8524649 | pubmed:meshHeading | pubmed-meshheading:8524649-... | lld:pubmed |
| pubmed-article:8524649 | pubmed:meshHeading | pubmed-meshheading:8524649-... | lld:pubmed |
| pubmed-article:8524649 | pubmed:meshHeading | pubmed-meshheading:8524649-... | lld:pubmed |
| pubmed-article:8524649 | pubmed:meshHeading | pubmed-meshheading:8524649-... | lld:pubmed |
| pubmed-article:8524649 | pubmed:meshHeading | pubmed-meshheading:8524649-... | lld:pubmed |
| pubmed-article:8524649 | pubmed:meshHeading | pubmed-meshheading:8524649-... | lld:pubmed |
| pubmed-article:8524649 | pubmed:meshHeading | pubmed-meshheading:8524649-... | lld:pubmed |
| pubmed-article:8524649 | pubmed:meshHeading | pubmed-meshheading:8524649-... | lld:pubmed |
| pubmed-article:8524649 | pubmed:meshHeading | pubmed-meshheading:8524649-... | lld:pubmed |
| pubmed-article:8524649 | pubmed:meshHeading | pubmed-meshheading:8524649-... | lld:pubmed |
| pubmed-article:8524649 | pubmed:meshHeading | pubmed-meshheading:8524649-... | lld:pubmed |
| pubmed-article:8524649 | pubmed:meshHeading | pubmed-meshheading:8524649-... | lld:pubmed |
| pubmed-article:8524649 | pubmed:meshHeading | pubmed-meshheading:8524649-... | lld:pubmed |
| pubmed-article:8524649 | pubmed:meshHeading | pubmed-meshheading:8524649-... | lld:pubmed |
| pubmed-article:8524649 | pubmed:meshHeading | pubmed-meshheading:8524649-... | lld:pubmed |
| pubmed-article:8524649 | pubmed:meshHeading | pubmed-meshheading:8524649-... | lld:pubmed |
| pubmed-article:8524649 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:8524649 | pubmed:articleTitle | A monoclonal antibody extends the half-life of an anti-HIV oligodeoxynucleotide and targets it to CD4+ cells. | lld:pubmed |
| pubmed-article:8524649 | pubmed:affiliation | Division of Experimental Oncology E, Istituto Nazionale Tumori, Milan, Italy. | lld:pubmed |
| pubmed-article:8524649 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8524649 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
